Lilly falls, while some obesity drug developers rise after Zealand Pharma-Roche deal

Shares of Eli Lilly LLY.N fall 1.46% to $812.04 premarket, while those of other obesity drug developers rise

Swiss drugmaker Roche ROG.S acquired rights to an obesity therapy by Denmark's Zealand Pharma ZELA.CO in a collaboration deal worth up to $5.3 billion

The agreement covering Zealand's petrelintide, signals renewed efforts by Roche to catch up with obesity market leaders Novo Nordisk NOVOb.CO and LLY

U.S.-listed shares of Novo fall 4.12% to $74.89 before the bell

Shares of obesity drug developers Viking Therapeutics VKTX.O rise 2% to $27.05, Structure Therapeutics GPCR.O gain 7.11% to $21.99

In the last 12 months, LLY shares have risen ~12%, VKTX has fallen ~58%, GPCR down ~42%